Speech Registration in Symptomatic Memory Impairment

Effects of Family Audio Recordings on Depression, Cognitive Function, and Sleep Quality of Individuals With Alzheimer's Disease: A Randomized Controlled Trial

PURPOSE

To explore the effects of family audio recordings on depression, cognitive function, and sleep quality among individuals with Alzheimer's disease in nursing homes.

METHOD

A randomized controlled study design was used, and 107 participants with Alzheimer's disease were stratified and randomly assigned to groups based on Clinical Dementia Rating Scale scores. The control group received usual care and health education, and the experimental group received usual care, health education, and a family audio recording intervention.

RESULTS

The experimental group showed significantly lower depression scores compared to the control group post-intervention. A within-group comparison of sleep quality scores in the experimental group was significantly different. At post-intervention, cognitive function scores in the control group significantly decreased compared to before the intervention.

CONCLUSION

Family audio recording interventions helped alleviate depression symptoms in individuals with Alzheimer's disease, improved their sleep quality, and delayed the progression of cognitive decline to some extent. [Journal of Gerontological Nursing, 51(1), 42-48.].

Using Self-Administered Game-Based Cognitive Assessment to Screen for Degenerative Dementia: A Pilot Study

BACKGROUND

The earlier detection of dementia is needed as cases increase yearly in the aging populations of Taiwan and the world. In recent years, the global internet usage rate has gradually increased among older people. To expand dementia screening and provide timely medical intervention, a simple self-administrated assessment tool to assist in easily screening for dementia is needed.

OBJECTIVE

The two-part goal of this pilot study was, first, to develop a Game-Based Cognitive Assessment (GBCA) tool, and then, to evaluate its validity at early screening for patients with cognitive impairment.

METHOD

The researchers recruited 67 patients with neurocognitive disorders (NCDs) and 57 healthy controls (HCs). Each participant underwent the GBCA and other clinical cognitive assessments (CDR, CASI, and MMSE), and filled out a questionnaire evaluating their experience of using the GBCA. Statistical analyses were used to measure the validity of the GBCA at screening for degenerative dementia.

RESULTS

The average GBCA scores of the HC and NCD groups were 87 (SD = 7.9) and 52 (SD = 21.7), respectively. The GBCA correlated well with the CASI (r2 = 0.90, p <  0.001) and with the MMSE (r2 = 0.92, p <  0.001), indicating concurrent validity. The GBCA cut-off of 75/76 corresponded to measurements of sensitivity, specificity, and area under curve of 85.1%, 91.5%, and 0.978, respectively. The positive predictive value was 91.9%, and the negative predictive value was 84.4%. The results of the user-experience questionnaire for the HC and NCD groups were good and acceptable, respectively.

CONCLUSION

The GBCA is an effective and acceptable tool for screening for degenerative dementia.

Impairments of attention in Alzheimer's disease

Alzheimer's Disease (AD) is characteristically perceived as primarily being a disorder of episodic memory, with prominent attentional impairments more typically being associated with other neurodegenerative conditions, such as Dementia with Lewy Bodies. However, attention is also affected early on in Alzheimer's, particularly in individuals with young onset and atypical syndromes. In addition, some initial symptoms that are apparently due to episodic memory loss may be secondary to failures of attentional processes. This review delineates the various attentional impairments that can be observed in patients with AD, and addresses them through the conceptual framework of attention proposed by Posner and Petersen. It also describes how current knowledge of the development of AD has influenced our understanding of how these deficits arise. Finally, there is a brief summary of the effects of current AD treatments on attentional processes, and how future pharmacological approaches might better target these deficits.